Observations placeholder

Nilutamide (INN, USAN, BAN) (brand names Nilandron (US), Anandron (CA)) is a synthetic, non-steroidal, pure antiandrogen used in the treatment of advanced-stage (metastatic) prostate cancer and was the second non-steroidal antiandrogen to be marketed after flutamide. Nilutamide acts as a potent and selective competitive silent antagonist of the androgen receptor (AR), which prevents testosterone and other androgens from activating the AR Because most prostate cancer cells rely on activation of the AR for growth and survival, nilutamide can extend life in men with prostate cancer

Nilutamide is used in prostate cancer in combination with a GnRH analogue at a dosage of 300 mg daily for the first 4 weeks of treatment, and 150 mg once daily thereafter It is not indicated as a monotherapy in prostate cancer Nilutamide has a half-life of approximately two days, which allows for once-daily administrationIn addition to prostate cancer, nilutamide has also been studied in and used as a component of hormone replacement therapy in trans women

General side effects of non-steroidal antiandrogens, including nilutamide, include gynecomastia, breast pain/tenderness, hot flashes, depression, fatigue, and sexual dysfunction In addition, relative to other non-steroidal antiandrogens, nilutamide has been uniquely associated with mild and reversible visual disturbances (31%), a disulfiram-likealcohol intolerance (19%), and interstitial pneumonitis (1–2% (which can progress to pulmonary fibrosis), and has a higher incidence of nausea (27%) and vomiting than other non-steroidal antiandrogens There is also a risk of hepatoxicity with nilutamide, though occurrence is very rare and the risk is significantly less than with flutamide The unique adverse effects of nilutamide, and especially its risk of interstitial pneumonitis, have limited its clinical use relative to other non-steroidal antiandrogens. From a safety standpoint, bicalutamide is clinically preferred over both nilutamide (due to interstitial pneumonitis) and flutamide (due to hepatotoxicity) in regards to choice of non-steroidal antiandrogen.

On Jan, 21, 2016: 165 people reported to have side effects when taking Nilandron. Among them, 2 people (1.21%) have Hallucination.

Time on Nilandron when people have Hallucination  :

Gender of people who have Hallucination when taking Nilandron  :

On Jan, 21, 2016: 165 people reported to have side effects when taking Nilandron. Among them, 18 people (10.91%) have Death.